544611 — Mahamaya Lifesciences Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsHighly SpeculativeMicro CapNeutral

Annual income statement for Mahamaya Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	PROSPECTUS	PROSPECTUS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,135	899	1,371	1,616	2,641
Cost of Revenue
Gross Profit	85.5	144	186	224	374
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	1,091	848	1,289	1,496	2,415
Operating Profit	44	51.1	82.2	120	227
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	39	37.2	51	74.3	173
Provision for Income Taxes
Net Income After Taxes	26.2	27.2	37.5	53.8	128
Net Income Before Extraordinary Items
Net Income	26.2	27.2	37.5	53.8	128
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	26.2	27.2	37.5	53.8	128
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.12	1.16	1.6	2.29	5.47